Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan in moderate-severe COVID-19
NCT05083000Phase 1Unknown
- Sponsor
- National University Hospital
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of topotecan in coronavirus disease 2019 (COVID-19), sponsored by National University Hospital. Primary endpoint: Maximal tolerable dose of Topotecan at 14 days. Status: unknown.
02
Drugs
topotecan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05083000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083000.